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Abstract
Background: Previous studies suggest central nervous system involvement in chronic fatigue syndrome (CFS), yet
there are no established diagnostic criteria. CFS may be difficult to differentiate from clinical depression. The study’s
objective was to determine if spectral coherence, a computational derivative of spectral analysis of the
electroencephalogram (EEG), could distinguish patients with CFS from healthy control subjects and not erroneously
classify depressed patients as having CFS.
Methods: This is a study, conducted in an academic medical center electroencephalography laboratory, of 632
subjects: 390 healthy normal controls, 70 patients with carefully defined CFS, 24 with major depression, and 148
with general fatigue. Aside from fatigue, all patients were medically healthy by history and examination. EEGs were
obtained and spectral coherences calculated after extensive artifact removal. Principal Components Analysis
identified coherence factors and corresponding factor loading patterns. Discriminant analysis determined whether
spectral coherence factors could reliably discriminate CFS patients from healthy control subjects without
misclassifying depression as CFS.
Results: Analysis of EEG coherence data from a large sample (n = 632) of patients and healthy controls identified 40
factors explaining 55.6% total variance. Factors showed highly significant group differentiation (p < .0004) identifying 89.5%
of unmedicated female CFS patients and 92.4% of healthy female controls. Recursive jackknifing showed predictions were
stable. A conservative 10-factor discriminant function model was subsequently applied, and also showed highly significant
group discrimination (p < .001), accurately classifying 88.9% unmedicated males with CFS, and 82.4% unmedicated male
healthy controls. No patient with depression was classified as having CFS. The model was less accurate (73.9%) in
identifying CFS patients taking psychoactive medications. Factors involving the temporal lobes were of primary importance.
Conclusions: EEG spectral coherence analysis identified unmedicated patients with CFS and healthy control subjects
without misclassifying depressed patients as CFS, providing evidence that CFS patients demonstrate brain physiology
that is not observed in healthy normals or patients with major depression. Studies of new CFS patients and
comparison groups are required to determine the possible clinical utility of this test. The results concur with other
studies finding neurological abnormalities in CFS, and implicate temporal lobe involvement in CFS pathophysiology.
Background
Fatigue is one of the most common presenting com-
plaints, accounting for a 10-25% prevalence of patients
presenting to primary care physicians (PCP) [1]. The
extensive differential diagnosis of fatigue encompasses a
wide spectrum of illnesses including, but not limited to
endocrine disorders, infections, cancer, medication side
effects, sleep disorders, seizures, autoimmune diseases,
obesity, drug abuse, malingering, and depression [2].
Fortunately, most of these illnesses have characteristic
clinical presentations often with confirmatory laboratory
tests.
Yet there remain significantly fatigued patients where
no underlying diagnosis can be securely established. In
the past, such patients were often dismissed as having
some form of uncertain psychiatric disorder-typically
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depression with symptoms of somatization. However,
within this ‘unclassifiable’ but severely fatigued patient
population a subset stood out with normal pre-morbid
personalities and whose pre-morbid lives were successful
and fulfilling. These patients, however, had suddenly
become unusually fatigued after an undetermined illness
and for whom the subsequent disabling weakness and
fatigue endured for more than six months (often years)
beyond the resolution of the initial illness. Some, but
not all, patients would report intermittent lymphadeno-
pathy and/or low grade fever often with corresponding
worsening of their fatigue. Yet, no clear etiology could
be found. The term Chronic Fatigue Syndrome (CFS)
came to be applied to this group where a suspicion of
organic etiology persisted but could not be confirmed
[2,3].
Since common psychiatric disorders, particularly
depression, often cause fatigue and since psychiatric
diagnoses may be difficult to objectively and reliably
confirm, many continued to reasonably wonder about
the role of an as of yet identified form of depression as
the cause of CFS. However, it was found that many
patients with CFS suffer from co-existing psychiatric
disorders only after becoming ill with CFS. Moreover, in
30-50% of patients no co-existing psychiatric disorders
[4,5] can be demonstrated. In addition, a carefully con-
trolled trial of fluoxetine in patients with CFS failed to
improve fatigue, even in those patients with a concomi-
tant major depression [6].
To better identify this perplexing patient population,
the U.S. Centers for Disease Control (CDC) convened a
group of experts to establish a set of strict diagnostic
criteria for CFS. The resultant criteria have become
known as the CDC or Fukuda criteria [3]. These criteria,
available as a multi-page evaluation form, serve investi-
gators and clinicians studying CFS to assure that their
patient populations are well identified and comparable
across studies. CFS is, therefore, not a synonym for pro-
longed, disabling fatigue although the distinction may be
difficult upon initial evaluation. In this paper we use the
term CFS to mean CDC-defined CFS.
CFS-which constitutes 0.5-2.5% of primary care refer-
rals and 10-15% of tertiary care referrals for fatigue [1]
-remains without confirmatory laboratory tests and can
be difficult to distinguish from depression. Between 1
and 8 in 1000 U.S. adults meet the CDC criteria [7].
The CDC estimates that cost to the U.S. economy from
lost productivity alone (not including medical care
costs) is $9 billion annually [8].
There exists published evidence that CFS may have its
underpinnings in organic disease especially within the
central nervous system (CNS), although not all studies
have found such abnormalities. Studies of the CNS in
CFS have included psychometric assessment of
cognition [9,10], magnetic resonance imaging [11-13],
functional MRI [14,15], in vivo MR spectroscopy [16,17],
single-photon emission computed tomography [18],
positron emission tomography [19], neuroendocrine stu-
dies of hypothalamic function [20-22], and studies of
the autonomic nervous system [23-25].
A link with infection and CFS also has been reported
following infection with Epstein-Barr virus, Ross River
virus, Coxiella burnetii [26], Borrelia burgdorferi [27],
parvovirus B19 [28], human herpesvirus-6 [29], and
enteroviruses [30]. Novel retroviruses may also be
involved [31,32] but that possibility has been challenged
[33]. All these infectious agents have the potential to be
CNS pathogens. The evidence of neurologic involvement
in CFS, and the possible role of infectious agents in trig-
gering and perpetuating CFS, is summarized in a recent
review [34].
Symptoms suggesting the possibility of subtle ence-
phalitis in CFS, along with the documented association
of CFS with several neurotropic infectious agents,
caused us to examine the role of electroencephalo-
graphic (EEG) studies in this illness. However, simple
visual inspection of EEG has rarely provided valuable
information in CFS, aside from allowing exclusion of
epilepsy and classic encephalopathy. A study utilizing
EEG Spectral Analysis [35] reported no significant dif-
ferences of spectral power in any EEG frequency bands
during sleep between subjects with CFS and their non-
fatigued co-twins. Only studies requiring stressful condi-
tions such as repetitive muscular exercise [36] and sleep
deprivation [37] have documented EEG spectral differ-
ence in CFS.
Accordingly, we undertook an exploration of spectral
coherence, a more complex computational derivative of
EEG spectral data, which estimates connectivity between
brain regions [38-40]. We hypothesized that results
would, first, serve to confirm a consistent pattern of
brain difference in CFS and, second, provide estimates
of the potential for an EEG based diagnostic test for
CFS.
Methods
Study Population
A total sample of 632 subjects was selected from an
existing EEG database of patients referred to and stu-
died at the Developmental Neurophysiology Laboratory,
Children’s Hospital Boston. Subject groupings, total sub-
jects per group, mean age plus standard deviation per
group, and medication status at time of study are shown
in Table 1.
Healthy Controls
A sample of 390 healthy control subjects, all of whom
had participated in a large study of normative aging
[41,42], served as a control group. All subjects were of
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normal intelligence, medication free, and screened to
exclude past or current medical, neurologic or psychia-
tric illness. No subject in this group had EEG findings
to suggest an underlying seizure disorder or encephalo-
pathic process. The healthy control subjects were
divided into two sub-groups, females (n = 197) and
males (n = 193).
CFS Patients
Seventy patients, all of whom were referred for com-
plaint of disabling fatigue, met the CDC criteria for CFS
(the CFS group) [3]. All patients included in this group
completed a standardized questionnaire and underwent
physical examinations and a battery of laboratory tests
to rule out other fatiguing illnesses, and all were classi-
fied as having CFS according to an algorithm based on
these clinical and laboratory data. EEGs were obtained
on patients who reported episodes of impaired cognition
(characteristic of the vast majority of patients seen in
this practice) and who agreed to undergo the procedure
(most of those to whom the procedure was offered).
None of the included CFS patients demonstrated clinical
or EEG evidence of a seizure disorder. In order to assess
the possible effect of psychoactive medications and gen-
der on the EEG results, the subjects were divided into
four sub-groups: unmedicated females (n = 38), unmedi-
cated males (n = 9), medicated females (n = 18), and
medicated males (n = 5). The CFS group was included
to determine and evaluate differences between healthy
control subjects and healthy CFS patients.
Depression Comparison Group
Twenty-four otherwise medically healthy patients met
the DSM-IV criteria for major depression, diagnosed
[43] by their referring psychiatrist, blinded to the goals
of this study. Disabling fatigue is a characteristic of
major depression [44]. All members of this population
had been referred for EEG to rule out evidence for sei-
zures and/or encephalopathy and no included patient
had EEG evidence to support either diagnosis. These
patients were similarly divided into four sub-groups by
gender and medication: unmedicated females (n = 10),
unmedicated males (n = 7), medicated females (n = 4),
and medicated males (n = 3). This group of patients
with major depression was included to determine
whether a discriminant function developed to distin-
guish CFS from controls might incorrectly classify
depressed patients as having CFS.
Patients with Unspecified Fatigue
One-hundred and forty-eight subjects carried the pri-
mary complaint of prolonged fatigue of undetermined
origin. They were all referred for EEG to rule out an
underlying seizure disorder or encephalopathic process.
We have no further information beyond the referring
physician’s written diagnosis. Medication and health sta-
tus was also determined by routine questionnaire at
time of EEG study. Patients who indicated underlying
medical disease, who did not confirm fatigue as a pri-
mary complaint, and/or with subsequent EEGs showing
clear evidence of epilepsy or encephalopathy were
excluded. The referring physicians had not rigorously
evaluated these subjects by the CDC criteria, and thus it
cannot be determined how many had the diagnosis of
CFS. This population is most likely comprised of
patients with CFS, depression, sleep disorders, and/or
other undiagnosed illnesses. This group was similarly
divided into unmedicated females (n = 60), unmedicated
males (n = 17), medicated females (n = 63), and medi-
cated males (n = 8). This group of patients with unspe-
cified fatigue was included solely to assure adequacy of
population variance in the large group of subjects used
to develop coherence factors by principal components
analysis (PCA) [45].
Informed Consent
All participants gave their informed consent in accor-
dance with the protocols approved by the Institutional
Review Boards for research with human subjects of the
respective referring hospitals, the Brigham and Women’s
Hospital (BWH), the Massachusetts General Hospital
(MGH), and the Children’s Hospital Boston (CHB). All
subjects were participants in one or more of the follow-
ing four CHB protocols where EEGs were performed:
Table 1 Patient Subgroups
Unmedicated (Total n = 531)
Category Total Mean Age (SD)
Control Females 197 46.5 (18.6)
Control Males 193 44.3 (18.2)
Chronic Fatigue Syndrome Females 38 42.2 (10.6)
Chronic Fatigue Syndrome Males 9 38.6 (11.4)
Depressed Females 10 45.8 (17.6)
Depressed Males 7 47.2 (11.0)
Fatigued Females 60 41.8 (9.3)
Fatigued Males 17 39.7 (8.6)
Medicated (Total n = 101)
Category Total Mean Age (SD)
Chronic Fatigue Syndrome Females 18 43.3 (13.6)
Chronic Fatigue Syndrome Males 5 32.3 (12.4)
Depressed Females 4 37.5 (24.3)
Depressed Males 3 33.9 (5.4)
Fatigued Females 63 41.6 (11.6)
Fatigued Males 8 32.3 (16.2)
Subject Cohort: numbers per group, mean ages (SD = standard deviation).
Controls = Unmedicated, normal control subjects, healthy by physician
evaluation,
CFS = Patients meeting CDC criteria for chronic fatigue syndrome, otherwise
healthy
Fatigue = Referred patients with non-specific fatigue, CFS status unknown,
otherwise healthy
Depression = Physician referred DSM-IV criteria for depression, otherwise
healthy.
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Computerized Brain Wave Testing; Age Related
Changes of Cognition in Health and Disease; Neurophy-
siology of CFS; QEEG Changes in Patients with CFS.
Measurements and Data Analyses
Methodological issues and solutions
Critiques of neurophysiological investigations typically
focus on three potential, methodological sources of
error: First, failure to stabilize subject state (e.g., waking,
drowsy). Second, failure to remove or otherwise manage
classic forms of EEG artifact (e.g., eye movement, eye
blink, muscle) with failure to recognize that EEGs
appearing clean by visual inspection may yet contain
significant artifact [46]. Third, capitalization upon
chance-applying statistical tests to too many variables
and incorrectly reporting those that appear significant
by chance as supporting the experimental hypothesis
[45,47-49]. We designed our methods to specifically
address these key issues.
EEG data collection: Artifact and state management at time
of data collection
EEG data from all 632 subjects were obtained from 32
gold-cup scalp electrodes affixed by collodion after care-
ful measurement by a registered EEG technologist. Elec-
trode locations, shown in Figure 1, formed a subset of
the standard 10-10 EEG electrode locations [50]. EEG
data were gathered in the awake, alert, eyes closed state
by an EEG technologist, naïve to study goals but specifi-
cally trained in the following protocol. Subjects were
periodically aroused and given brief breaks either every
1-2 minutes or whenever drowsiness was evident in the
EEG-whichever came first. Subjects were then instructed
to open their eyes, blink frequently, and move to a com-
fortable position. Data collection subsequently resumed
in the eyes closed state. Data were sampled at 256 Hz
after filtering from 1-100 Hz using Grass™ EEG ampli-
fiers, and digitally recorded for subsequent quantitative
analyses. All amplifiers were individually calibrated prior
to each study. At the end of the data collection, digitized
EEG data were visually inspected by the EEG technolo-
gist and those EEG epochs during breaks or showing
movement artifact, electrode artifact, eye blink storms,
drowsiness, and/or bursts of muscle activity were
visually identified and eliminated. In our experience
expert visual identification of drowsiness has been found
equal or superior to detection by automated detection
algorithms [51]. EEGs were marked so that all channels
during an artifact epoch would be excluded from subse-
quent analyses. After visual inspection, data were low
pass filtered below 50 Hz with an additional 60 Hz
mains rejection notch filter. Residual eye blink and eye
movement artifacts, which may be surprisingly promi-
nent even during the eyes closed state, were removed
using the source component technique [52,53]
implemented in the BESA3.5™ software package.
Visually, these combined techniques resulted in EEG
data that appeared largely artifact free, with rare excep-
tions of low level temporal muscle artifact and residual
frontal and anterior temporal slow eye movement,
which remain capable of contaminating subsequent ana-
lyses. The final reduction of such residual contamination
is discussed below.
Calculation of Spectral Coherence Variables
Approximately 15 minutes of EEG collected and pro-
cessed as noted above were transformed to Current
Source Density measures (BESA software), a reference-
free condition sensitive to underlying cortex and rela-
tively insensitive to deep/remote EEG sources [54,55].
Spectral coherence measures were derived from the 1-
32 Hz range, in 16 two Hz wide spectral bands, result-
ing in 7936 unique coherence variables. (NB: The 32 by
32 electrode matrix gives 1024 possible coherence values
but the matrix diagonal has a value of 1-each electrode
to itself-and half of the 992 remaining values duplicate
the other half, leaving 496 unique coherences per spec-
tral band. Multiplication by the 16 spectral bands results
in 7936 unique spectral coherence values per subject).
Coherence data calculation was performed as outlined
by Saltzberg [38] using a Nicolet™ software package.
Further artifact reduction by multivariate regression
Unfortunately, artifact cannot be removed from an
entire EEG data set by direct elimination of electrodes
and/or frequencies where a particular artifact may
appear most easily seen. For example, although eye
blink typically dominates low spectral frequencies in
prefrontal regions, its non-sinusoidal waveform will gen-
erate harmonics at higher frequencies that will overlap
with higher frequency spectral signals that are non-arti-
factual (brain generated). Furthermore, the spatial field
of eye blink can also be expected to involve contamina-
tion of more distant electrodes. A similar argument
applies to temporal-frontal muscle artifact.
A good approach to further reduce residual artifactual
contamination of coherence data involves multivariate
regression. Semliltsch has demonstrated [56] that by
identifying a signal proportional to a known source of
artifact, this signal’s contribution to scalp recorded data
may be effectively removed by statistical regression pro-
cedures. Residual vertical eye movement and blink pro-
duce slow EEG delta spectral signals in the frontopolar
channels FP1 and FP2 which may be estimated by the
average of the 0.5 and 1.0 Hz spectral components from
these channels after EEG spectral analysis by Fast Four-
ier Transform (FFT) [57]. Similarly, horizontal eye
movement may be estimated by the average of the 0.5-
1.0 Hz spectral components from anterior temporal
electrodes F7 and F8. Little meaningful information of
brain origin is typically found at this slow frequency in
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the indicated channels in the absence of extreme pathol-
ogy (e.g., brain tumors, trauma, and abscess). Muscle
activity, in contrast, tends to peak at frequencies above
those of current interest. Accordingly, 30-32 Hz FFT
components were considered to be largely representative
of muscle contamination, especially as recorded from
the separate averages of prefrontal (FP1, FP2), anterior
temporal (F7, F8), mid-temporal (T7, T8), and posterior
temporal (P7, P8) electrodes. These electrodes are the
most often contaminated by muscle as they are physi-
cally closest to the source of the artifact (frontal and
temporal muscles). The six artifact measures, two very
slow delta and four high frequency beta, were submitted
as independent variables to a multiple regression analy-
sis (BMDP2007™-6R) [58] used to individually predict
each of the coherence variables (see below) treated as
dependent variables. The residuals of this process con-
stitute coherence data that definitionally cannot be pre-
dicted by the artifact measures. By adding the residual
data from each subject to the original neurophysiologic
mean data, artifact free coherence measures were gener-
ated which are used for all subsequent analyses.
Variable number reduction; creation of coherence factors
Data for all electrodes and for all EEG frequencies pro-
duce a large variable number-7936 for our study. To
facilitate subsequent statistical analyses, we undertook
Principal Components Analysis (PCA) as an objective
technique to meaningfully reduce variable number [45].
Our coherence data were first normalized (centered and
shifted to have unit variance) so that eventual factors
reflect deviations from the average response. To avoid
loss of sensitivity by a priori data limitation, an
Figure 1 Standard EEG Electrode Names and Positions. Head in vertex view, nose above, left ear to left. EEG electrodes: Z: Midline: FZ:
Midline Frontal; CZ: Midline Central; PZ: Midline Parietal; OZ: Midline Occipital. Even numbers, right hemisphere locations; odd numbers, left
hemisphere locations: Fp: Frontopolar; F: Frontal; C: Central; T: Temporal; P: Parietal; O: Occipital. The standard 19, 10-20 electrodes are shown as
black circles. An additional subset of 17, 10-10 electrodes are shown as open circles.
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‘unrestricted’ form of PCA was applied [59] allowing all
coherence variables per subject to enter analysis. By
employment of an algorithm based upon singular value
decomposition (SVD) [59], a data set of uncorrelated
(orthogonal) principal components or factors [45,59,60]
was developed in which the identification of a small
number of factors (following Varimax rotation [61])
describe an acceptably large amount of variance [62].
Varimax rotation enhances factor contrast yielding
higher loadings for fewer factors whilst retaining factor
orthogonality and has become “...the most widely
accepted and employed standard for orthogonal rotation
of factors...” (p.145) [63]. Although not the only PCA
method applicable to large, asymmetrical matrices (7936
variables by 632 cases as in the current study), SVD
(which can be used to solve undetermined and over
determined systems of linear equations [57]) is among
the most efficient in our experience [59]. This approach
to variable number reduction has been successfully used
in a prior study of EEG spectral coherence in infants
[59].
Discriminating groups of subjects by use of EEG spectral
coherence variables
Two-group discriminant function analysis (DFA) [63-66]
produces a new canonical variable, the discriminant
function, which maximally separates the groups and is
based on a weighted combination of the entered vari-
ables. DFA defines the significance of the group separa-
tion, summarizes the classification of each subject, and
provides approaches to the prospective classification of
subjects not involved in discriminant rule generation by
means of the Jackknifing technique [67,68] or by classifi-
cation of entirely new populations. The BMDP2007™
statistical package [58] was employed for DFA (program
7M). Jackknifing is a technique often used in DFA to
estimate prospective classification success [67,68]. In
Jackknifing-for two groups DFA as undertaken in this
paper-the discriminant function is formed on all sub-
jects but one. The left out subject is subsequently classi-
fied. This initial left out subject is then folded back into
the group (hence “jackknifing”), another subject is left
out, the DFA preformed again, and the newly left out
subject classified. This process is repeated until each
individual subject has been left out and classified. The
measure of classification success is based upon a tally of
the correct classifications of the left out subjects. This is
frequently referred to as the leaving-one-out process.
Alternatively, more than a single subject may be left out
for each iteration which may be referred to as the leav-
ing-many-out process. In our experience a more reliable
estimate of prospective classification success results
from a “leaving 20% out” test. For that reason, we used
a random number generator within BMDP-4M (stepwise
discriminant analysis) that permits random assignment
of each subject to a training set (80% of the subjects,
used to create the discriminant) and a test set (20% of
the subjects, used to estimate prospective classification).
(NB: The algorithm used by BMDP does not always pro-
vide a precise 80%/20% split and the ratio of control to
experimental subjects within each selected sub-group
reflect random chance.) We performed this exercise ten
times.
Factor description; relating PCA outcome factors to input
coherence variables
Individual outcome factors are individually formed as
linear combinations of all input variables with the
weight or loading of each coherence variable upon a
particular factor determined by the PCA computation
[63]. As is the general case for PCA, the “meanings” of
outcome factors may be discerned by inspection of the
loadings of the input variables upon each individual fac-
tor [45,63]. To facilitate an understanding of outcome
factors for this study, where there are large number of
input variables, the factor loadings were treated as if
they were primary neurophysiologic data and displayed
topographically [69,70]. Display of a representative sam-
ple of the highest loading values has typically [71] served
to facilitate an understanding of individual factor mean-
ing as shown in Figure 2.
Results
Identification and Selection of Spectral Coherence
Variables
Variance distribution among the resulting coherence
factors was favorable: 2014 factors described over 99%,
302 described 90.03%, 37 described 50.32%, 7 described
26.01% and 1 described 8.25% of the total variance. The
first 40 factors-accounting for 55.64% of total variance-
were chosen for analysis, exceeding Bartlett’s recom-
mendation [72] and resulting in a conservative sample
size to variable ratio of 235:40 or 6:1 [73] for the initial
DFA described below.
Discriminating Groups Using Spectral Coherence
Variables
The primary discriminant analysis was based on the 197
unmedicated female controls and 38 unmedicated
female CFS patients. Female subjects were chosen
because in most case series and epidemiologic studies of
CFS, females outnumber males [7].
When all 40 coherence factors were forced to enter
the DFA, there was a highly significant (p < 0.0004)
group differentiation by Wilks’ Lambda, with Rao’s
approximation. The unmedicated female CFS patients
were identified with 89.5% accuracy and the female con-
trols with comparable 92.4% accuracy. Age did not sig-
nificantly differ between these two groups. The
statistically significant result, with all 40 factors as
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variables forced to enter, establishes that these two
groups differ on the basis of variables generated from
EEG based coherence data.
Stepwise DFA was then utilized to identify a factor
subset that best described the group difference. Ten fac-
tors (Figure 2, Table 2) entered the model resulting in a
highly significant discrimination (p < .001) and equiva-
lent classification success rate: unmedicated female con-
trols 89.85%; unmedicated females with CFS 86.8%.
Loadings of the 10 best factors (Table 2) determined to
be useful in subsequent group discriminations are topo-
graphically displayed in Figure 2.
Figure 2 Graphic Representation of 10 Coherence Factor Loadings. EEG coherence factor loadings. Heads in top view, scalp left to image
left; index electrode within heads and frequency range in Hz below. Region-Colors: Location, magnitude, and sign (red = positive; blue =
negative) of maximally loading coherence on factor. Arrow-Colors: Direction of association indicated by arrow (red = increased coherence in CFS;
yellow = decreased coherence in CFS).
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The results of the 10 jackknifing trials are shown in
Table 3. The average success for the ten trials is
reported for the control (87.14%) and CFS females
(86.2%). Each of these ten iterations generates a unique
canonical discriminant variable for each test set member
on the basis of the corresponding training set data. As a
separate measure of classification success a 2-group ana-
lysis of variance (ANOVA) is performed for the discri-
minant variable on test set subjects (BMDP -7D). All of
the 10 iterations reached significance, eight at or below
the p < 0.0003 level, one at the p < 0.006 level and one
at the p < 0.02 level.
By both classification success and ANOVA, results
were positive for use of spectral coherence data in pro-
spective classification.
Applying the Discriminant Function to Other Groups
The 10-factor discriminant function derived from the
unmedicated female subjects was then tested on the
other patient groups. Of note, 8 of the 9 (88.9%) unme-
dicated CFS males, whose data were not included in for-
mation of the discriminant formation, were correctly
classified.
The discriminant function was applied to male and
female CFS subjects who were taking psychoactive med-
ications. Although it performed considerably better than
chance, the discriminant performed less well than it had
with unmedicated subjects: 14/18 (77.8%) of medicated
female CFS patients and 3/5 (60%) of medicated male
CFS patients were accurately classified.
For patients with unspecified fatigue whether medi-
cated or unmedicated, 46.6% were assigned to the CFS
classification. As the true diagnosis of these subjects is
not known, accuracy of the classification cannot be
inferred.
Finally, when the discriminant function was applied to
all four subgroups of the 24 patients with major depres-
sion, none of the depressed patients were falsely classi-
fied as having CFS.
Characteristics of Coherence Variable Differences
between CFS and Normal Subjects
There was no clear predominant side (right vs. left) or
EEG spectral band involved in the 10 factors that were
the best discriminators. However, there were clear dif-
ferences in the brain regions involved in the ten most
discriminating coherence factors, as follows: Temporal
region (9/10), central (8/10), frontal (5/10), occipital (3/
10), and parietal (1/10) region. (Figure 2)
Discussion
The first goal of this study was to explore meaningful
reduction, by principal components analysis (PCA), of a
large data set of artifact-free EEG spectral coherence data
created from an adult population containing healthy con-
trols and patients with CFS, major depression, and unspe-
cified severe fatigue. Coherence is taken to represent the
degree of functional connectivity or coupling between two
different brain regions at a chosen frequency.
The second goal was to explore the utility of the PCA-
reduced data set in differentiating CFS patients from
normal subjects without falsely classifying depressed
patients as having CFS. Many studies have found evi-
dence of nervous system involvement in CFS, but no
large, controlled investigations of the value of EEG spec-
tral coherence in patients with CFS had been reported.
Spectral coherence has proven useful in conditions
Table 2 Coherence Loadings on 10 Best Coherence
Factors
Factor Loading Range (Hz) EEG Electrodes Involved
1 +0.91 2-6 OZ ¬ ® FT9, F7, FP1
2-6 O1 ¬ ® FT9, F7, FP1
2-6 O2 ¬ ® FT9, F7, FP1
2 +0.82 24-28 OZ ¬ ® T7, FC5, F3, C3
3 -0.80 20-26 T8 ¬ ® FC6, CP6
19 -0.64 18-28 F3 ¬ ® CP5, FC5, FC1, CP2
27 +0.61 6 T7 ¬ ® P7, FC6, T8, CP6
6 T8 ¬ ® FC5, T7, CP5, P7
21 -0.61 4-10 C3¬ ® FC5, FC2, C4, T8, F8
4-10 C4 ¬ ® C3, FC5, F8
14-26 C3 ¬ ® C4, T8, F8
14-26 C4 ¬ ® C3, T7
24 +0.58 8 F4 ¬ ® F3, P7, TP9, CP2, P8, TP10
28 +0.57 2-8 T7 ¬ ® FC1, C3, CP1
37 +0.55 14-24 P4 ¬ ® CZ, CP1, O2, P8
20 -0.35 8-12 FC1¬ ® CP1, F7, FP1, FP2
See Figure 1 for scalp location of indicated electrodes.
Table 3 Recursive Jackknifing by Leaving 20% Out: Test
Set Classification Accuracy
Trial Control %
Correct
CFS %
Correct
df F p
1 35/41 85.36 8/9 88.89 1,14 38.09 0.0000
2 34/38 89.47 5/5 100.00 1,5 20.42 0.0063
3 32/39 82.05 9/10 90.00 1,19 39.66 0.0000
4 36/41 87.80 8/9 88.89 1,11 41.38 0.0000
5 37/41 90.24 5/6 83.33 1,6 9.17 0.0232
6 35/39 89.74 8/10 80.00 1,14 22.51 0.0003
7 33/43 76.74 8/9 88.89 1,14 29.51 0.0001
8 41/47 87.23 7/9 77.78 1,11 29.89 0.0002
9 40/44 90.90 11/14 78.57 1,28 51.75 0.0000
10 36/39 92.31 6/7 85.71 1,10 43.47 0.0001
Mean 87.14 86.21
One-Way Analysis of Variance (F); 2-tailed. Results are number and percent
correctly classified of Test Set, df = degrees of freedom, p = probability value
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where standard EEG is seldom found to be diagnostic
[59,71,74,75].
First goal, creation of artifact free coherence factors by
PCA
Utilizing the full subject population (Table 1, n = 632) we
were successful in reducing the initial 7936 coherence vari-
ables per subject to 40 orthogonal (uncorrelated) factors
per subject which described 55.6% of the total, initial var-
iance. In other words, PCA condensed over half the infor-
mation (variance) contained in the initial 7936 variables
into just 40 new variables (outcome factors). One benefit
of this almost 7936:40 or 200 fold reduction in data dimen-
sionality over the entire population is a parallel reduction
in the likelihood for capitalization on chance of the sort
that may occur during subsequent statistical analyses when
they involve large numbers of variables [48]. An additional
benefit to this ‘hands-off’ data reduction is that it requires
no advance or a priori coherence variable selection by the
investigators, eliminating any possible variable selection
bias. Bartels refers to this as allowing the intrinsic data
structure of the population to select variables [45].
In utilizing this PCA based approach, it is important
to include all subjects in the initial PCA, even including
subjects with related but not completely defined clinical
diagnoses-in our case medicated patients and generally
fatigued patients with incomplete diagnoses. Among-
subject variance within the population is responsible for
factor formation. For instance, had factor formation
been limited to healthy normal control subjects exclu-
sively, the degree of variance introduced by fatigue,
depression and medications would have, therefore, been
absent and factors potentially important to group
separation might never have been formed.
Finally, the data underwent an initial multiphase arti-
fact control process (see Methods) performed across the
entire population. It is highly unlikely that the final, pro-
cessed coherence data contained significant eye move-
ment or muscle contamination. Indeed prior to PCA,
the coherence data were processed so as to be uncorre-
lated with six classic measures of eye and muscle arti-
fact. Thus it is unlikely that our study findings reflect
artifactual group differences.
Finally, subject selection for the primary study groups
(healthy controls, CFS, depression) was rigorous and
performed by clinical experts in their fields on the basis
of standardized, published criteria. This will facilitate
replication including sample selection for future studies
here and/or elsewhere.
Second goal, differentiating CFS patients from healthy
controls
Our study findings indicate that EEG spectral coherence
data, recorded in the waking eyes closed state, differ
significantly between healthy control female subjects
and otherwise healthy female patients with CDC-defined
CFS. Our 40 coherence factors, significantly separated
these two index subject groups at p < 0.001. This funda-
mental finding indicates that CFS patients manifest pat-
terns of functional brain coupling that differ from those
of normal controls. Such a difference of CFS brain phy-
siology may help explain known differences in cognition,
memory, sleep, and affect that afflict CFS patients (see
Background).
We also found that a small subset of as few as 10 coher-
ence factors were able to accurately identify (by stepwise
discriminant analysis) these same unmedicated female
subjects (CFS 86.8% accuracy, control 89.8% accuracy).
When the rules generated by this analysis on unmedicated
females were prospectively applied to unmedicated CFS
males and healthy control males who were not involved in
the discriminant function creation, true prospective classi-
fication accuracy remained high (CFS 88.9%, control
82.4%). In addition, when the classification rules were
applied to the entire depressed population, none were fal-
sely, prospectively, classified as having CFS.
Jackknifed classification techniques, employed to pro-
vide estimates for the prospective success rate for appli-
cation of the discriminant rules to new sets of
unmedicated female subjects (CFS and normal), was
successful. By a re-iterative leaving 20% out processes,
accuracy for controls was 87.1% and for CFS was 86.2%,
(Table 3). Thus the discriminant should prove effective
on entirely new samples. However, that hypothesis must
be tested on a large, new set of patients with CFS and
comparison groups (healthy and with other fatiguing ill-
nesses) to assure the accuracy and utility of EEG spec-
tral coherence as a diagnostic aid.
Speculations
The less than 100% accuracy of our spectral coherence
based classification function could reflect a deficiency
in the CDC criteria for CFS, and/or a deficiency in the
coherence-based discriminant itself, and/or unexplored
physiological variability even within carefully CDC-
defined CFS. For example, multiple etiologic agents
have been identified as potential triggers of the CFS
phenotype [26], each with the potential for a slightly
differing impact upon the central nervous system
(CNS) and, hence, on EEG spectral coherence. The
possibility of sub-grouping [76] CFS on the basis of
coherence and other objective CNS measures (e.g.,
MRI, SPECT/PET, neuropsychology) may be a fruitful
area for further exploration. Subgrouping could result
in a broader set of objectively derived CNS measures
from neurophysiology and other neuroimaging techni-
ques that might eventually become the diagnostic ‘gold
standard’ for CFS.
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When applied to patients with CFS who were taking
psychoactive medications at the time of testing, the 10-
factor model was less accurate (females, 77.8% accuracy;
males, 60.0% accuracy). Since psychoactive medications
directly affect the brain, the organ being examined by
EEG, it is possible that these medications may modify
EEG measures such that their accuracy is compromised.
Alternatively, these medications may have had a thera-
peutic clinical effect on brain function (connectivity),
thus causing some CFS patients to electrophysiologically
resemble normal controls. Supporting this hypothesis is
the observation that some patients were tested while on
psychoactive medications because they refused to dis-
continue them being convinced from past experiences
that this might worsen their clinical condition. Thus
another fruitful area for further exploration is to deter-
mine if EEG spectral coherence is a useful index mea-
sure in assessing medication treatment response.
Given a lack of detailed clinical information, it is not
possible to determine classification accuracy within our
Unspecified Fatigue population. When the 10 coherence
factor discriminant is applied to this group 46.6% are
classified as CFS. This is broadly consistent with the
published estimate that the prevalence of true CFS
among patients seeking care from tertiary specialists for
prolonged fatigue can be as high as 35% [1].
The finding of bilateral temporal lobe involvement in 9
of 10 factors is of potential clinical significance. The 10
coherence factors did not collectively localize to any
other single brain region. This greater temporal lobe
involvement is consistent with the global memory
impairment in CFS reported by Marcel [9] and Daly [77].
It is also interesting that one neurotropic virus associated
with CFS, human herpesvirus-6, appears to selectively
affect the temporal lobes and has recently been asso-
ciated with temporal lobe seizure disorders [78-80].
Future plans
Our immediate plans call for enlarging our population to
prospectively test and refine current findings. This will pri-
marily involve recruiting additional patients with depres-
sion and non-CFS prolonged fatigue as well as additional
patients with CDC-defined CFS-especially males. All
patients will have equivalent evaluations: clinical and beha-
vioral as well and neurophysiological. We plan to evaluate
a population of CFS patients before and after beginning
medications. We also hope to develop specific classifica-
tion rules to separate four diagnostic groups: CFS, non-
CFS prolonged fatigue, depression, and healthy controls.
We plan to search for CFS-gender interactions. All this
will require substantially larger populations than now
available to us. Finally, within the CFS population we will
employ cluster analysis, as successfully applied by
Montironi and Bartels [76] in another research area, to
search for consistent CFS subpopulations.
Conclusions
EEG-derived spectral coherence factors accurately classify
unmedicated subjects with rigorously-defined CFS, and
reliably distinguish them from matched healthy control
subjects, while at the same time not falsely classifying
depressed patients as having CFS. This finding is in accord
with other objective evidence that CFS is associated with
organic, brain-based pathophysiology [34]. The discrimi-
nant function based on the identified coherence factors is
less successful in patients on psychoactive medications,
which might reflect a palliative effect of the medications.
EEG coherence measures, perhaps in combination with
other neuroimaging data, may ultimately prove to provide
a valuable diagnostic test for CFS as well as an objective
means to evaluate potential CFS therapies.
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